Latest News and Press Releases

NMD Pharma to present compelling preclinical data highlighting the potential of ClC-1 ion channel inhibition to improve disease symptoms and progression in MuSK myasthenia gravis at the MGFA...

NMD Pharma to present compelling preclinical data highlighting the potential of ClC-1 ion channel inhibition to improve disease symptoms and progression in MuSK myasthenia gravis at the MGFA...

New compelling results demonstrate 18 months of both sustained reduction in immunoglobulin G antibodies and sustained improvement in gMG symptoms in pivotal Vivacity-MG3 study and open label extension...

New compelling results demonstrate 18 months of both sustained reduction in immunoglobulin G antibodies and sustained improvement in gMG symptoms in pivotal Vivacity-MG3 study and open label extension...

New York, March 10, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) welcomes the U.S. Food and Drug Administration (FDA) approval of the expanded indication of...

The first investigational FcRn blocker to demonstrate sustained disease control over 24 weeks in antibody positive adult patients: anti-AChR+, anti-MuSK+, anti-LRP4+ Nipocalimab demonstrated a...

First FcRn blocker to demonstrate superiority in Myasthenia Gravis - Activities of Daily Living score (MG-ADL) a over placebo when added to standard of care over 24 weeks in antibody positive...

NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients Aarhus, Denmark, 11 June 2024 – NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel...

NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients Aarhus, Denmark, 11 June 2024 – NMD Pharma A/S, a clinical-stage biotech company dedicated to developing...

CORAL GABLES, Fla., May 28, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...